Chemotherapy for gastric cancer that recurs after adjuvant chemotherapy with S-1

Japanese Journal of Clinical Oncology

Volumn 38, Issue 11, 2008, Pages 786-789

  Shitara, Kohei ^a   Muro, Kei ^a   Ura, Takashi ^a   Takahari, Daisuke ^a   Yokota, Tomoya ^a   Sawaki, Akira ^a   Kawai, Hiroki ^a   Ito, Seiji ^a   Yamamura, Yoshitaka ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Adjuvant chemotherapy; Gastric cancer; Recurrence; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; DOCETAXEL; IRINOTECAN; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PATIENT ASSESSMENT; RETROSPECTIVE STUDY; STOMACH CANCER; SURVIVAL RATE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; SALVAGE THERAPY; STOMACH NEOPLASMS;

EID: 55149117787     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyn096     Document Type: Article

References (14)

1. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998;34:1715-20.
2. Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 2000;58:191-7.
3. Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 2003;89:2207-12.
4. Uedo N, Narahara H, Ishihara R, Takiuchi H, Goto M, Fujitani K, et al. Phase II study of a combination of irinotecan and S-1 in patients with advanced gastric cancer (OGSG0002). Oncology 2007;73:65-71.
5. Yamaguchi K, Shimamura T, Hyodo I, Koizumi W, Doi T, Narahara H, et al. Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer. Br J Cancer 2006;94:1803-8.
6. Boku N, Yamamoto S, Shirao K, Doi T, Sawaki A, Koizumi W, et al. Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912). J Clin Oncol 2007;25: (June 20 Supplement). Abstract LBA4513.
7. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol 2008;9:215-21.
8. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357: 1810-20.
9. Pujade-Lauraine E, Paraiso D, Cure H, Germann N, Lortholary A, Lucas V, et al. Predicting the effectiveness of chemotherapy (Cx) in patients with recurrent ovarian cancer (ROC): A GINECO study. Proc Am Soc Clin Oncol 2002;21: Abstract 829.
10. Takashima A, Shirao K, Hirashima Y, Takahari D, Okita N, Akatsuka S, et al. Chemosensitivity of patients with recurrent esophageal cancer receiving perioperative chemotherapy. Dis Esophagus 2008; April 22 [Epub ahead of print].
11. Futatsuki K, Wakui A, Nakao I, Sakata Y, Kambe M, Shimada Y, et al. Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group. Gan To Kagaku Ryoho 1994;21:1033-8.
12. Taguchi T, Sakata Y, Kanamaru R, Kurihara M, Suminaga M, Ota J, et al. Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: A Japanese Cooperative Study Group trial (group A). Gan To Kagaku Ryoho 1998;25: 1915-24.
13. Mai M, Sakata Y, Kanamaru R, Kurihara M, Suminaga M, Ota J, et al. A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer: A cooperative study group trial (group B). Gan To Kagaku Ryoho 1999;26:487-96.
14. Yamada Y, Shirao K, Ohtsu A, Boku N, Hyodo I, Saitoh H, et al. Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol 2001;12:1133-7.